# Memorial Sloan Kettering Cancer Center

Source: https://onco.cc/institutions/mskcc/  
OnCo record `mskcc` (Institution). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The world's top-ranked cancer hospital, home of MSK-IMPACT sequencing, the dostarlimab rectal cancer study, and CAR-T pioneers.

## Summary

Memorial Sloan Kettering Cancer Center is a New York cancer centre founded in 1884, NCI-designated as comprehensive and ranked first in the Newsweek/Statista World's Best Specialized Hospitals list for oncology, which makes it the reference point against which other cancer hospitals are measured. Its firsts include MSK-IMPACT, an FDA-authorised tumour sequencing panel that feeds OncoKB and cBioPortal, co-development of CD19 CAR-T cell therapy with Sadelain's group, the dostarlimab study in mismatch-repair-deficient rectal cancer led by Andrea Cercek, and the Paige AI digital pathology spin-out. It runs one of the largest oncology trial portfolios in the United States. The open question for a centre this large is how quickly its knowledge reaches practice elsewhere, a bottleneck OnCo tracks explicitly. Its people and trials pages are the best way into the detail.

## Fields

- Kind: Institution
- Last checked: 2026-09-04
- City: New York, US
- Type: cancer-center
- NCI designation: comprehensive
- Website: https://www.mskcc.org

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Memorial_Sloan_Kettering_Cancer_Center
- Official website: https://www.mskcc.org

## Connected records

- collections: [cBioPortal for Cancer Genomics](https://onco.cc/collections/cbioportal/), [Newsweek/Statista World's Best Specialized Hospitals: Oncology](https://onco.cc/collections/newsweek-hospitals/), [OncoKB](https://onco.cc/collections/oncokb/)
- companies: [Break Through Cancer](https://onco.cc/companies/break-through-cancer/), [Paige AI](https://onco.cc/companies/paige/)
- technologies: [Active surveillance of papillary microcarcinoma](https://onco.cc/technologies/active-surveillance-thyroid/), [Asking people how they are, every week, as a treatment in its own right](https://onco.cc/technologies/rejuv-measure-epro-as-treatment/), [Cancer variant knowledgebases and molecular tumour boards](https://onco.cc/technologies/variant-knowledgebases/), [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [Comprehensive genomic profiling](https://onco.cc/technologies/cgp/), [Dietary supplements during cancer treatment: interactions and harms](https://onco.cc/technologies/dietary-supplements-treatment-interactions/), [Digital pathology & AI](https://onco.cc/technologies/digital-pathology-ai/), [Electronic patient-reported outcome (ePRO) symptom monitoring](https://onco.cc/technologies/epro-symptom-monitoring/), [Minoxidil for persistent chemotherapy- and endocrine-therapy hair loss](https://onco.cc/technologies/minoxidil-chemotherapy-alopecia/), [Platelet-rich plasma for hair after cancer treatment](https://onco.cc/technologies/hair-platelet-rich-plasma/), [St John's wort: an interaction to avoid](https://onco.cc/technologies/st-johns-wort-interaction/), [Virchow / Virchow2 (Paige, MSK)](https://onco.cc/technologies/virchow/)
- drugs: [Dostarlimab](https://onco.cc/drugs/dostarlimab/)
- people: [Alexander Drilon](https://onco.cc/people/alexander-drilon/), [Alfred P. Sloan Jr.](https://onco.cc/people/alfred-sloan/), [Andrea Cercek](https://onco.cc/people/andrea-cercek/), [Bob T. Li](https://onco.cc/people/bob-li/), [Charles F. Kettering](https://onco.cc/people/charles-kettering/), [Charles L. Sawyers](https://onco.cc/people/charles-sawyers/), [Charles M. Rudin](https://onco.cc/people/charles-rudin/), [Clifford A. Hudis](https://onco.cc/people/clifford-hudis/), [Daniel K. Ludwig](https://onco.cc/people/daniel-ludwig/), [David B. Solit](https://onco.cc/people/david-solit/), [David H. Koch](https://onco.cc/people/david-koch/), [Dean F. Bajorin](https://onco.cc/people/dean-bajorin/), [Deborah Schrag](https://onco.cc/people/deb-schrag/), [Eileen M. O'Reilly](https://onco.cc/people/eileen-oreilly/), [Evelyn Lauder](https://onco.cc/people/evelyn-lauder/), [Eytan M. Stein](https://onco.cc/people/eytan-stein/), [Ghassan K. Abou-Alfa](https://onco.cc/people/ghassan-abou-alfa/), [Gilles Salles](https://onco.cc/people/gilles-salles/), [Gregory J. Riely](https://onco.cc/people/gregory-riely/), [Helena A. Yu](https://onco.cc/people/helena-yu/), [Howard I. Scher](https://onco.cc/people/howard-scher/), [Ingo K. Mellinghoff](https://onco.cc/people/ingo-mellinghoff/), [Jae H. Park](https://onco.cc/people/jae-park/), [Jason S. Lewis](https://onco.cc/people/jason-lewis/), [Jimmie Holland](https://onco.cc/people/jimmie-holland/), [John D. Rockefeller Jr.](https://onco.cc/people/john-d-rockefeller-jr/), [John Jacob Astor III](https://onco.cc/people/john-jacob-astor-iii/), [Jonathan E. Rosenberg](https://onco.cc/people/jonathan-rosenberg/), [Julio Garcia-Aguilar](https://onco.cc/people/julio-garcia-aguilar/), [Komal Jhaveri](https://onco.cc/people/komal-jhaveri/), [Luis A. Diaz Jr.](https://onco.cc/people/luis-diaz/), [Mark E. Robson](https://onco.cc/people/mark-robson/), [Michael A. Postow](https://onco.cc/people/michael-postow/), [Michael F. Berger](https://onco.cc/people/michael-berger/), [Michael J. Morris](https://onco.cc/people/michael-morris/), [Monica Morrow](https://onco.cc/people/monica-morrow/), [Mortimer Zuckerman](https://onco.cc/people/mortimer-zuckerman/), [Nai-Kong V. Cheung](https://onco.cc/people/nai-kong-cheung/), [Paul B. Chapman](https://onco.cc/people/paul-chapman/), [Paul K. Paik](https://onco.cc/people/paul-paik/), [Raajit K. Rampal](https://onco.cc/people/raajit-rampal/), [Robert J. Motzer](https://onco.cc/people/robert-motzer/), [Rona Yaeger](https://onco.cc/people/rona-yaeger/), [Ross L. Levine](https://onco.cc/people/ross-levine/), [Saad Z. Usmani](https://onco.cc/people/saad-usmani/), [Sandra P. D'Angelo](https://onco.cc/people/sandra-dangelo/), [Sean Parker](https://onco.cc/people/sean-parker/), [Selwyn M. Vickers](https://onco.cc/people/selwyn-vickers/), [Shanu Modi](https://onco.cc/people/shanu-modi/), [Sharon Belvin](https://onco.cc/people/sharon-belvin/), [Steven M. Horwitz](https://onco.cc/people/steven-horwitz/), [Valerie W. Rusch](https://onco.cc/people/valerie-rusch/), [Vicky Makker](https://onco.cc/people/vicky-makker/), [Vinod P. Balachandran](https://onco.cc/people/vinod-balachandran/), [William D. Tap](https://onco.cc/people/william-tap/), [Yelena Y. Janjigian](https://onco.cc/people/yelena-janjigian/)
- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/), [Retinoblastoma](https://onco.cc/cancers/retinoblastoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)
- trials: [Autogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering)](https://onco.cc/trials/autogene-cevumeran-phase-1/), [AZUR-1](https://onco.cc/trials/azur-1/), [Beat AML Master Trial](https://onco.cc/trials/beat-aml-master-trial/), [OPRA](https://onco.cc/trials/opra/)
- ideas: [A global first-in-human network for academic cancer trials with single ethics review](https://onco.cc/ideas/idea-fund-global-academic-phase-one-network/), [A mandatory trial line in every tumour board recommendation](https://onco.cc/ideas/idea-tr1-tumour-board-trial-line-item/), [A tumour board assistant that cites its evidence and tracks outcomes](https://onco.cc/ideas/idea-data-tumour-board-evidence-assistant/), [An open supplement-drug interaction checker built into oncology prescribing](https://onco.cc/ideas/idea-moon-supplement-interaction-database/), [Broad research consent as a routine step of the cancer pathway](https://onco.cc/ideas/idea-data-consent-in-the-pathway/), [Confirm or refute the harm of antioxidant supplements during chemotherapy](https://onco.cc/ideas/idea-nl-antioxidant-supplement-harm-confirmation/), [Cut the nerve supply to tumours with old drugs](https://onco.cc/ideas/idea-nerve-tumour-blockade/), [Give immunotherapy in the morning](https://onco.cc/ideas/idea-chronotherapy-immunotherapy/), [Is aneuploidy itself a druggable vulnerability?](https://onco.cc/ideas/idea-targeting-aneuploidy/), [Map metabolic dependencies in the patient, not the dish](https://onco.cc/ideas/idea-metabolic-vulnerability-mapping/), [One-two punch: clear senescent cells after chemotherapy](https://onco.cc/ideas/idea-senolytics-after-chemo/), [Regionally delivered mesothelin CAR-T with PD-1 blockade](https://onco.cc/ideas/idea-mesothelin-car-t-regional/), [Shared splice-derived neoantigens as off-the-shelf vaccine targets](https://onco.cc/ideas/idea-splice-neoantigens/), [Weekly symptom check-ins with automatic alerts as standard of care on treatment](https://onco.cc/ideas/idea-moon-pro-monitoring-standard/), [What actually holds T cells at the tumour border?](https://onco.cc/ideas/idea-immune-exclusion-drivers/), [What decides which disseminated cells ever colonise?](https://onco.cc/ideas/idea-dtc-colonisation-determinants/), [What makes a neoantigen actually immunogenic?](https://onco.cc/ideas/idea-neoantigen-immunogenicity-rules/), [Which patients' blood clones will become leukaemia after treatment?](https://onco.cc/ideas/idea-chip-risk-modifiers/)
- key papers: [A revised classification system and recommendations from the Baltimore consensus meeting for neoplastic precursor lesions in the pancreas](https://onco.cc/key-papers/paper-basturk-baltimore-consensus-precursor-lesions-ajsp-2015/), [A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma](https://onco.cc/key-papers/paper-hayashi-squamous-basal-like-pancreatic-nat-cancer-2020/), [Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain](https://onco.cc/key-papers/paper-pao-egfr-t790m-acquired-resistance-plos-med-2005/), [Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers](https://onco.cc/key-papers/paper-yu-acquired-resistance-rebiopsy-egfr-ccr-2013/), [Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels](https://onco.cc/key-papers/paper-ricciuti-tmb-pd-l1-levels-jama-oncol-2022/), [Basch: asking patients to report symptoms online during chemotherapy improved survival](https://onco.cc/key-papers/paper-basch-epro-survival-jama-2017/), [Cercek 2022: six months of dostarlimab alone made rectal cancer disappear in every patient with mismatch-repair deficiency](https://onco.cc/key-papers/paper-cercek-dostarlimab-rectal-nejm-2022/), [CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma](https://onco.cc/key-papers/paper-checkmate-067-10-year-nejm-2025/), [CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma](https://onco.cc/key-papers/paper-checkmate-649-lancet-2021/), [Clinical and genomic characterization of ERBB2-altered gallbladder cancer: exploring differences between an American and a Chilean cohort](https://onco.cc/key-papers/paper-mondaca-erbb2-gallbladder-us-chile-jco-go-2024/), [Clinical sequencing defines the genomic landscape of metastatic colorectal cancer](https://onco.cc/key-papers/paper-yaeger-metastatic-colorectal-genomic-landscape-cancer-cell-2018/), [Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention](https://onco.cc/key-papers/paper-giraldo-gallbladder-msk-impact-ccr-2022/), [Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes](https://onco.cc/key-papers/paper-offin-rb1-tp53-transformation-risk-jto-2019/), [Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status](https://onco.cc/key-papers/paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022/), [Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial](https://onco.cc/key-papers/paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019/), [Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer](https://onco.cc/key-papers/paper-arbour-kras-co-mutation-outcomes-ccr-2018/), [EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes](https://onco.cc/key-papers/paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019/), [Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection](https://onco.cc/key-papers/paper-park-hrd-pancreatic-platinum-ccr-2020/), [Hu 2018: evaluating mismatch repair deficiency in pancreatic adenocarcinoma, challenges and recommendations](https://onco.cc/key-papers/paper-hu-mismatch-repair-deficiency-pancreatic-adenocarcinoma-ccr-2018/), [Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer](https://onco.cc/key-papers/paper-balachandran-neoantigen-quality-long-term-survivors-nature-2017/), [INDIGO: vorasidenib, the first targeted drug for IDH-mutant low-grade glioma](https://onco.cc/key-papers/paper-indigo-nejm-2023/), [Integrative genomic profiling of human prostate cancer](https://onco.cc/key-papers/paper-taylor-integrative-genomic-profiling-cancer-cell-2010/), [Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer](https://onco.cc/key-papers/paper-makohon-moore-metastases-driver-homogeneity-nat-genet-2017/), [Molecular and clinical determinants of targeted therapy treatment in biliary tract cancer](https://onco.cc/key-papers/paper-cowzer-biliary-targeted-therapy-determinants-ccr-2026/), [Molecular determinants of response to anti-PD-1 and anti-PD-L1 blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing](https://onco.cc/key-papers/paper-rizvi-targeted-ngs-immunotherapy-determinants-jco-2018/), [Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data](https://onco.cc/key-papers/paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019/), [Nonoperative management of mismatch repair-deficient tumors](https://onco.cc/key-papers/paper-cercek-nonoperative-management-mismatch-repair-deficient-tumours-nejm-2025/), [Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy (OPRA)](https://onco.cc/key-papers/paper-garcia-aguilar-opra-organ-preservation-jco-2022/), [Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer](https://onco.cc/key-papers/paper-gucalp-bicalutamide-ar-positive-tbcrc011-ccr-2013/), [Precancerous neoplastic cells can move through the pancreatic ductal system](https://onco.cc/key-papers/paper-makohon-moore-precursor-cells-ductal-system-nature-2018/), [Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies](https://onco.cc/key-papers/paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017/), [Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms](https://onco.cc/key-papers/paper-lowery-prospective-germline-exocrine-pancreatic-jnci-2018/), [Quail and Joyce 2013: microenvironmental regulation of tumour progression and metastasis](https://onco.cc/key-papers/paper-quail-joyce-microenvironment-metastasis-natmed-2013/), [Regional differences in gallbladder cancer pathogenesis: insights from a multi-institutional comparison of tumor mutations](https://onco.cc/key-papers/paper-narayan-gallbladder-regional-mutations-cancer-2019/), [Ribas and Wolchok 2018: cancer immunotherapy using checkpoint blockade](https://onco.cc/key-papers/paper-ribas-wolchok-checkpoint-blockade-science-2018/), [Rizvi 2015: the mutational landscape determines who responds to PD-1 blockade in lung cancer](https://onco.cc/key-papers/paper-rizvi-mutational-landscape-pd1-science-2015/), [RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer](https://onco.cc/key-papers/paper-sethna-rna-neoantigen-vaccine-long-lived-t-cells-nature-2025/), [Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer](https://onco.cc/key-papers/paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023/), [SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization](https://onco.cc/key-papers/paper-baine-sclc-subtype-immunohistochemistry-jto-2020/), [SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer](https://onco.cc/key-papers/paper-mu-sox2-lineage-plasticity-science-2017/), [SU2C-PCF: integrative clinical genomics of advanced prostate cancer](https://onco.cc/key-papers/paper-robinson-integrative-clinical-genomics-advanced-prostate-cell-2015/), [The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer](https://onco.cc/key-papers/paper-schoenfeld-smarca4-alterations-lung-ccr-2020/), [Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion](https://onco.cc/key-papers/paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019/), [Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs](https://onco.cc/key-papers/paper-kris-lung-cancer-mutation-consortium-jama-2014/)
- roadmaps: [Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherapy for mismatch repair-deficient disease, ctDNA-guided treatment and organ preservation](https://onco.cc/roadmaps/colorectal-roadmap/), [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/), [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)
- institutions: [Breast Cancer Research Foundation](https://onco.cc/institutions/bcrf/), [Damon Runyon Cancer Research Foundation](https://onco.cc/institutions/damon-runyon/), [Howard Hughes Medical Institute](https://onco.cc/institutions/hhmi/), [Ludwig Cancer Research](https://onco.cc/institutions/ludwig-cancer-research/), [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/), [National Comprehensive Cancer Network (NCCN)](https://onco.cc/institutions/nccn-org/), [New York Proton Center](https://onco.cc/institutions/new-york-proton-center/), [Parker Institute for Cancer Immunotherapy](https://onco.cc/institutions/parker-institute/), [Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine](https://onco.cc/institutions/weill-cornell-meyer-cancer-center/)
- bottlenecks: [Acquired resistance to every therapy](https://onco.cc/bottlenecks/b-resistance/), [Data silos](https://onco.cc/bottlenecks/b-data-silos/), [Knowledge reaches practice too slowly](https://onco.cc/bottlenecks/b-knowledge-diffusion/), [Metastasis is understood least and studied last](https://onco.cc/bottlenecks/b-metastasis-biology/)
- pathways: [Antigen presentation & immune editing](https://onco.cc/pathways/antigen-presentation-immunoediting/), [Cancer metabolism](https://onco.cc/pathways/cancer-metabolism/), [Cancer neuroscience (nerve-tumour signalling)](https://onco.cc/pathways/cancer-neuroscience/), [Cancer stem cells & phenotypic plasticity](https://onco.cc/pathways/cancer-stem-cells-plasticity/), [Cellular senescence](https://onco.cc/pathways/senescence/), [Chromosomal instability & aneuploidy](https://onco.cc/pathways/chromosomal-instability/), [Circadian control](https://onco.cc/pathways/circadian-control/), [Clonal evolution & minimal residual disease](https://onco.cc/pathways/clonal-evolution/), [Clonal haematopoiesis (CHIP)](https://onco.cc/pathways/clonal-haematopoiesis/), [Epigenetic reprogramming](https://onco.cc/pathways/epigenetic-reprogramming/), [Ferroptosis & regulated cell death](https://onco.cc/pathways/ferroptosis-cell-death/), [Hippo-YAP/TAZ](https://onco.cc/pathways/hippo-yap/), [Inflammation & NF-κB](https://onco.cc/pathways/inflammation-nfkb/), [JAK-STAT signalling](https://onco.cc/pathways/jak-stat/), [KEAP1-NRF2 antioxidant pathway](https://onco.cc/pathways/keap1-nrf2/), [mRNA translation (eIF4F / mTOR)](https://onco.cc/pathways/mrna-translation-eif4f/), [RNA splicing](https://onco.cc/pathways/rna-splicing/), [TGF-β signalling](https://onco.cc/pathways/tgf-beta/), [The metastatic cascade](https://onco.cc/pathways/metastatic-cascade/), [Tumour dormancy](https://onco.cc/pathways/tumor-dormancy/), [Tumour microenvironment (TME)](https://onco.cc/pathways/tumor-microenvironment/)

---
JSON: https://onco.cc/api/v1/entities/mskcc.json